查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1978740

冠状动脉绕道手术手术市场：依移植类型、手术类型、应用、最终用户划分，全球预测，2026-2032年

Coronary Artery Bypass Grafts Market by Graft Type, Procedure Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，冠状动脉绕道手术手术市场价值将达到 208.9 亿美元，到 2026 年将成长至 219.6 亿美元，到 2032 年将达到 298.8 亿美元，复合年增长率为 5.24%。

主要市场统计数据
基准年 2025 208.9亿美元
预计年份：2026年 219.6亿美元
预测年份 2032 298.8亿美元
复合年增长率 (%) 5.24%

对目前冠状动脉绕道手术手术的现状进行全面概述，重点介绍临床进展、技术进步以及对医疗保健提供者的营运影响。

本执行摘要首先简要概述了现代冠状动脉绕道手术移植术（CABG）的生态系统，重点阐述了正在重塑医疗服务模式的技术、临床和运营因素。过去十年，影像学、血管获取和手术全期管理技术的进步改变了临床路径，而手术方式的多样化也带来了新的技能要求、资金规划考量和患者选择模式。

快速的临床创新、手术多样化和供应链合作正在重塑冠状动脉再灌注途径和医疗保健重点。

由于技术创新、器械小型化和多学科诊疗模式的推动，冠状动脉绕道手术移植术领域正在经历变革。新兴技术正在缩小传统开胸手术与微创手术之间的差距，促使许多医疗机构重新评估临床路径，并将加速病患復健和减少住院资源作为优先事项。

本研究评估了 2025 年美国关税变化对移植材料供应、设备采购和供应链韧性的累积营运和采购影响。

2025年政策和贸易趋势带来的关税变化对冠状动脉绕道手术移植术相关技术的整个采购、製造和分销管道产生了连锁反应。这些政策措施显着影响了移植准备和供应系统中使用的进口器材、专用设备和组件的成本结构，迫使许多供应链相关人员重新评估其采购和库存策略。

有针对性的細項分析揭示了移植类型、手术技术、医疗环境和临床应用如何影响不同的临床和操作决策过程。

基于细分市场的分析揭示了每种移植类型、手术技术、最终用户环境和应用领域对临床和采购的不同影响。每种情况都存在独特的操作和实施方面的考量。在比较不同类型的移植时，如果长期通畅性是首要考虑因素，动脉移植往往是手术中的首选。另一方面，在某些解剖和临床情况下，静脉移植仍然占据主导地位，这会影响库存组成和外科医生培训的重点。

影响招募模式、筹资策略和临床专案设计的区域趋势（包括美洲、欧洲、中东、非洲和亚太地区）。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的各种手术组合、技术应用和供应链策略有显着影响。在美洲，三级医疗机构和综合医疗保健系统高度重视技术的推广，这些机构和系统能够支援资本密集技术和系统化的培训计画。这种环境有利于机器人手术和混合手术方式的快速试点，同时也要求提供关于其临床和营运效益的严格证据。

重新定义产品差异化和临床伙伴关係：设备、机器人和服务供应商之间的竞争格局和策略行动

冠状动脉绕道手术手术 (CABG) 领域的竞争格局反映了成熟手术器械製造商、新兴机器人和影像公司以及提供全面支援的服务型供应商之间的互动。主要企业持续投资于血管采集器械、吻合装置和耗材的迭代改进，旨在简化工作流程并降低治疗结果的差异性。同时，机器人和内视镜系统正在革新传统的手术室配置，促进技术提供者和临床中心之间开展共同开发和培训计画的合作协议。

临床和商业领导者需要采取切实可行的策略行动，以协调技术采用、采购弹性和人才发展，从而实现专案的永续成长。

产业领导者应优先考虑分阶段、循证的技术采纳方法，使临床目标、营运能力和财务管理保持一致。首先，应进行多学科评估，包括手术量、外科医生培训需求和手术全期流程，以确定各机构在哪些领域投资微创手术和机器人技术能够带来最大的临床和营运回报。儘早与临床促进者、护理领导者和供应链合作伙伴开展合作，将有助于製定切实可行的采纳计划，并为认证规划提供支援。

我们透过实证调查方法确保提供可操作的见解，这些方法结合了与临床医生的直接访谈、监管分析、文献综述和案例研究。

本执行摘要的研究基于多方面方法，旨在整合临床证据、营运经验和市场讯息，同时保持分析的严谨性。主要研究包括对心臟外科医生、循环系统专科护理师、相关医疗保健专业人员、采购经理和医院管理人员进行结构化访谈，以直接了解手术选择、培训限制和供应链优先事项。这些定性研究结果与同行评审的临床文献、指南文件以及记录手术结果和比较技术评估的註册资料进行了交叉比对。

简洁的整合，强调冠状动脉再灌注的实际进展，优先考虑技术可行性、操作可行性和供应链稳定性之间的平衡。

总之，冠状动脉绕道手术手术的发展并非处于完全替代阶段，而是处于实践演进阶段。微创技术、机器人技术和手术全期通讯协定的进步正在拓展治疗选择，并为改善患者体验创造机会，但诸如培训要求、资金限制和供应链考量等组织现实因素正在减缓变革的步伐。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：冠状动脉绕道手术手术市场：依移植类型划分

  • 动脉
  • 静脉

第九章：冠状动脉绕道手术手术市场：依手术类型划分

  • 常规泵浦上
  • 微创手术
    • 内视镜
    • 机器人
  • 非泵送

第十章：冠状动脉绕道手术手术市场：依应用领域划分

  • 多血管疾病
  • 单血管疾病

第十一章：冠状动脉绕道手术手术市场：依最终用户划分

  • 门诊手术中心
  • 心臟中心
  • 医院

第十二章：冠状动脉绕道手术手术市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：冠状动脉绕道手术手术市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章冠状动脉绕道手术手术市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国：冠状动脉绕道手术手术市场

第十六章 中国：冠状动脉绕道手术手术市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AtriCure, Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • ConMed Corporation
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • enVVeno Medical Corporation
  • Getinge AB
  • LivaNova PLC
  • Medtronic plc
  • Teleflex Incorporated
  • Terumo Corporation
  • Transonic Systems Inc.
  • Vascular Graft Solutions Ltd.
Product Code: MRR-2A0283E2559F

The Coronary Artery Bypass Grafts Market was valued at USD 20.89 billion in 2025 and is projected to grow to USD 21.96 billion in 2026, with a CAGR of 5.24%, reaching USD 29.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.89 billion
Estimated Year [2026] USD 21.96 billion
Forecast Year [2032] USD 29.88 billion
CAGR (%) 5.24%

A comprehensive orientation to the current coronary artery bypass graft environment highlighting clinical evolution, technology adoption, and operational implications for providers

This executive summary opens with a concise orientation to the contemporary coronary artery bypass graft ecosystem, framing the technological, clinical, and operational forces that are reshaping care delivery. Over the past decade, advances in imaging, conduit harvesting techniques, and perioperative management have altered clinical pathways, while procedural diversification has introduced new skill requirements, capital planning considerations, and patient selection paradigms.

Clinical teams are increasingly balancing traditional open techniques with less invasive approaches that aim to reduce recovery time and resource utilization. At the same time, hospitals and specialized centers are reassessing program structures to accommodate robotics, endoscopic instrumentation, and dedicated hybrid operating rooms. These shifts have implications for staffing models, training curricula, and capital allocation decisions across institutions.

Moreover, the patient population undergoing bypass procedures is evolving, with demographic trends and comorbidity profiles influencing graft selection and perioperative strategies. As a result, stakeholders must integrate clinical evidence, technology capability, and operational feasibility to design durable care pathways. The introduction prepares the reader to explore subsequent sections that examine landscape transformations, policy impacts, segmentation intelligence, regional dynamics, competitive positioning, and pragmatic recommendations for leaders aiming to refine their approach to coronary artery bypass graft care.

How rapid clinical innovations, procedural diversification, and supply chain partnerships are reshaping coronary revascularization pathways and institutional priorities

The coronary artery bypass graft landscape is undergoing transformative shifts driven by innovations in technique, device miniaturization, and multidisciplinary care models. Emerging technologies have narrowed the gap between traditional open surgery and less invasive strategies, prompting many centers to reevaluate clinical pathways to prioritize faster recoveries and reduced inpatient resource use.

Concurrently, procedural diversification is influencing workforce development and privileging policies. As minimally invasive endoscopic and robotic-assisted techniques gain traction alongside off-pump and conventional on-pump approaches, institutions face the dual challenge of ensuring procedural volume to maintain proficiency while investing in simulation and proctoring programs. This dynamic fosters collaborative relationships between cardiac surgeons, interventional cardiologists, anesthesiologists, and perioperative teams to optimize patient outcomes.

Supply chain innovation and vendor partnerships are also affecting adoption curves. Manufacturers are offering integrated systems and service models that lower the barrier to entry for smaller programs, while reimbursement environments and hospital resource constraints shape rollout timelines. In parallel, patient-centered care expectations-driven by shorter hospital stays and quicker return-to-function-are motivating providers to adopt evidence-informed protocols that support accelerated recovery without compromising long-term graft patency. Taken together, these shifts are redefining how institutions deliver coronary revascularization across the care continuum.

Assessing the cumulative operational and procurement consequences of United States tariff shifts in 2025 on graft supplies, device sourcing, and supply chain resilience

Policy and trade dynamics in 2025 introduced tariff changes that ripple across procurement, manufacturing, and distribution channels linked to coronary artery bypass graft technologies. These policy measures have had a pronounced effect on cost structures for imported instruments, specialized devices, and component materials used in graft preparation and delivery systems, prompting many supply chain stakeholders to reassess sourcing and inventory strategies.

As a consequence, procurement teams are increasingly emphasizing supplier diversification and regional manufacturing partnerships to mitigate exposure to cross-border policy volatility. Clinical leaders have responded by working with supply chain counterparts to identify clinically equivalent alternatives and to validate device interoperability to maintain procedural continuity. In parallel, contract negotiations with vendors have grown more intricate, with greater focus on total-cost-of-ownership clauses, service level agreements, and contingencies for customs-related delays.

Operationally, some institutions have accelerated investments in reusable instrumentation where clinically appropriate and enhanced sterilization capacity to offset lead-time risks. Regulatory compliance and quality assurance teams have also become more central to vendor selection, ensuring that alternative sources meet clinical performance expectations. Ultimately, the combined effect of trade policy shifts has underscored the importance of resilient procurement strategies and closer alignment between clinical, supply chain, and commercial stakeholders.

Targeted segmentation insights showing how graft type, procedure modality, care setting, and clinical application drive distinct clinical and operational decisions

Segmentation-based insights reveal differentiated clinical and procurement implications across graft types, procedure modalities, end-user settings, and applications, each carrying distinct operational and adoption considerations. When examining graft type distinctions, arterial conduits often command procedural preference where long-term patency is prioritized, whereas venous grafts remain a mainstay for specific anatomic and clinical scenarios, influencing inventory mix and surgeon training priorities.

Procedure type distinctions further nuance adoption pathways: conventional on-pump approaches anchor many institutional programs due to broad practitioner familiarity and predictable workflows, while off-pump techniques are leveraged in select populations to reduce cardiopulmonary bypass-related sequelae. Minimally invasive strategies, including endoscopic harvesting and robotic-assisted operations, are expanding into centers that can support advanced instrumentation and dedicated perioperative teams, and they necessitate coordinated investments in training, simulation, and case scheduling.

End-user segmentation underscores divergent operational requirements across ambulatory surgical centers, cardiac centers, and hospitals. Ambulatory facilities emphasize throughput, rapid recovery protocols, and lean inventory models, whereas specialized cardiac centers focus on high-acuity service portfolios and technology-intensive procedures. Hospitals balance both acute care responsibilities and broader surgical case mixes, requiring flexible supply agreements and cross-departmental coordination. Application-driven insights, differentiating multi-vessel disease from single-vessel disease, inform clinical pathway design and graft selection strategies, as patients with complex coronary anatomy often demand multi-disciplinary planning and resource-intensive perioperative care. These segmentation perspectives collectively guide targeted program design and procurement decisions.

Regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence adoption patterns, procurement strategies, and clinical program design

Regional dynamics exert a strong influence on procedural mix, technology adoption, and supply chain strategies across the Americas, Europe Middle East and Africa, and Asia-Pacific geographies. In the Americas, there is a pronounced emphasis on innovation diffusion within tertiary centers and integrated health systems that can underwrite capital-intensive technologies and structured training programs. This environment supports rapid piloting of robotics and hybrid approaches while demanding rigorous evidence of clinical and operational benefit.

Across Europe, the Middle East and Africa, regional heterogeneity leads to varied adoption profiles; established cardiac centers in high-income countries emphasize outcomes-driven implementation with strong regulatory oversight, whereas emerging markets prioritize scalable solutions that improve access to care. Consequently, vendor engagement strategies must be adapted to account for reimbursement frameworks, local clinical guidelines, and variable infrastructure capabilities.

The Asia-Pacific region displays a broad spectrum of adoption velocities, with several markets actively pursuing capacity expansion and modernization of cardiac surgical services. Strategic partnerships between manufacturers and regional distributors have been pivotal in expanding access to advanced instruments and training. Across all regions, differences in demographic trends, prevalence of coronary disease, and health system organization shape workforce planning, procedural selection, and capital investment decisions, requiring market-specific approaches to clinical integration and commercialization.

Competitive landscape and strategic behaviors among device, robotics, and service providers that are redefining product differentiation and clinical partnerships

Competitive dynamics in the coronary artery bypass graft ecosystem reflect an interplay between established surgical device manufacturers, emerging robotics and imaging companies, and service-oriented vendors offering integrated support. Leading device firms continue to invest in iterative improvements to conduit harvesting tools, anastomotic devices, and disposables that aim to simplify workflows and reduce variability in outcomes. At the same time, robotics and endoscopic systems are disrupting traditional operating room configurations, prompting collaborative agreements between tech providers and clinical centers for co-development and training programs.

Strategic differentiation increasingly rests on bundled solutions that combine hardware, consumables, data analytics, and educational services. Vendors that demonstrate a clear pathway to reduce operating time, improve patient recovery metrics, or lower complication rates secure stronger clinical advocacy and preference. Meanwhile, aftermarket service models, remote monitoring, and surgeon credentialing offerings have become competitive levers as hospitals seek predictable performance and reduced lifecycle costs.

Partnerships between device manufacturers and academic centers facilitate evidence generation and real-world validation, which in turn informs adoption and reimbursement conversations. Supply chain partnerships and regional manufacturing footprints are also shaping competitive positioning, particularly for stakeholders aiming to ensure continuity of supply and responsive service across diverse geographies.

Practical strategic actions for clinical and commercial leaders to align technology adoption, procurement resilience, and workforce development for sustainable program growth

Industry leaders should prioritize a phased, evidence-driven approach to technology adoption that aligns clinical objectives with operational capacity and financial stewardship. Begin by conducting multidisciplinary assessments of procedure volumes, surgeon training needs, and perioperative pathways to identify which minimally invasive or robotic investments will yield the greatest clinical and operational returns for a given institution. Early engagement with clinical champions, nursing leadership, and supply chain partners ensures realistic implementation timelines and supports credentialing plans.

Next, pursue supplier agreements that emphasize flexibility, training support, and outcome-linked service commitments to mitigate operational risk. Where tariff- or policy-related procurement exposures exist, diversify sourcing and consider regional manufacturing partnerships to improve lead-time reliability. Invest in simulation and proctoring programs to accelerate proficiency while protecting patient safety, and integrate robust data collection to track perioperative outcomes, resource use, and patient-reported recovery metrics.

Finally, foster collaborative relationships with payers and regulatory stakeholders to highlight value propositions rooted in improved recovery times, reduced complications, and optimized care pathways. By combining clinical rigor with pragmatic procurement and workforce planning, leaders can scale advanced coronary revascularization approaches in a manner that balances innovation with measurable improvements in patient care.

An evidence-driven research methodology combining primary clinician interviews, regulatory analysis, literature review, and operational case studies to ensure actionable insights

The research underpinning this executive summary draws on a multi-method approach designed to synthesize clinical evidence, operational experience, and market intelligence while preserving analytical rigor. Primary research involved structured interviews with cardiac surgeons, perfusionists, allied health professionals, procurement directors, and hospital administrators to capture firsthand perspectives on procedural selection, training constraints, and supply chain priorities. These qualitative insights were triangulated with peer-reviewed clinical literature, guideline documents, and registries that document procedural outcomes and comparative technique evaluations.

Secondary analysis incorporated regulatory filings and device approvals to understand product lifecycles and safety profiles, alongside public policy materials that contextualize procurement and trade dynamics. Additionally, site-level case studies explored implementation pathways for minimally invasive and robotic programs, highlighting resource allocation, staff competency development, and throughput impacts. Quality assurance measures included cross-validation of interview themes, methodological transparency regarding data sources, and peer review by clinical subject-matter experts to ensure that interpretations reflect current practice realities.

Together, these methods provide a structured, evidence-informed basis for the insights and recommendations offered in this summary, with an emphasis on operational applicability and clinical integrity.

A concise synthesis emphasizing pragmatic evolution in coronary revascularization balancing technological promise with operational feasibility and supply chain stability

In conclusion, the coronary artery bypass graft environment is in a period of pragmatic evolution rather than wholesale replacement. Advances in minimally invasive techniques, robotics, and perioperative protocols are expanding therapeutic options and creating opportunities for improved patient experiences, while institutional realities such as training requirements, capital constraints, and supply chain considerations temper the pace of change.

Policy shifts and tariff dynamics have highlighted the importance of procurement resilience and closer collaboration between clinical and supply chain leadership. Segmentation insights demonstrate that graft selection, procedural modality, and care setting each demand tailored strategies that accommodate local clinical expertise and infrastructure. Regionally, diverse adoption patterns underscore the value of context-specific approaches that align technology deployment with reimbursement, workforce capacity, and population health needs.

For organizations seeking to navigate this transition, the balanced path forward involves phased investment, rigorous outcome tracking, and strategic supplier partnerships that emphasize service, training, and supply continuity. By synthesizing clinical evidence with operational planning, providers and industry partners can improve patient outcomes while building programs that are sustainable and responsive to future innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coronary Artery Bypass Grafts Market, by Graft Type

  • 8.1. Arterial
  • 8.2. Venous

9. Coronary Artery Bypass Grafts Market, by Procedure Type

  • 9.1. Conventional On Pump
  • 9.2. Minimally Invasive
    • 9.2.1. Endoscopic
    • 9.2.2. Robotic
  • 9.3. Off Pump

10. Coronary Artery Bypass Grafts Market, by Application

  • 10.1. Multi Vessel Disease
  • 10.2. Single Vessel Disease

11. Coronary Artery Bypass Grafts Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals

12. Coronary Artery Bypass Grafts Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Coronary Artery Bypass Grafts Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Coronary Artery Bypass Grafts Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Coronary Artery Bypass Grafts Market

16. China Coronary Artery Bypass Grafts Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AtriCure, Inc.
  • 17.6. B. Braun Melsungen AG
  • 17.7. Baxter International Inc.
  • 17.8. ConMed Corporation
  • 17.9. CryoLife, Inc.
  • 17.10. Edwards Lifesciences Corporation
  • 17.11. enVVeno Medical Corporation
  • 17.12. Getinge AB
  • 17.13. LivaNova PLC
  • 17.14. Medtronic plc
  • 17.15. Teleflex Incorporated
  • 17.16. Terumo Corporation
  • 17.17. Transonic Systems Inc.
  • 17.18. Vascular Graft Solutions Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ARTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ARTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ARTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY VENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY VENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY VENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CONVENTIONAL ON PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CONVENTIONAL ON PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CONVENTIONAL ON PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ROBOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ROBOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MULTI VESSEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MULTI VESSEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MULTI VESSEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SINGLE VESSEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SINGLE VESSEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SINGLE VESSEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GCC CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. G7 CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 127. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NATO CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY GRAFT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA CORONARY ARTERY BYPASS GRAFTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)